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Summary
Background:  Autologous  chondrocyte  implantation  (ACI)  was  introduced  in  1987  in  Sweden  by
Brittberg and  Peterson  for  the  treatment  of  severe  chondral  defects  of  the  knee.  Here,  our
objective was  to  evaluate  mid-term  outcomes  of  ACI  in  young  athletic  patients  with  deep
chondral  defects  of  the  knee  after  trauma.
Hypothesis:  ACI  is  effective  in  ﬁlling  full-thickness  chondral  defects  of  the  knee.
Patients and  methods:  We  prospectively  monitored  14  patients,  with  International  Cartilage
Repair Society  grade  III  or  IV  lesions,  who  underwent  ACI  between  2001  and  2006.  Standard
evaluation  measurements  were  used.  Mean  age  at  surgery  was  37.7  years  (range,  30—45).  A
history of  surgery  on  the  same  knee  was  noted  in  ten  (67%)  patients.  The  defect  was  on  the
medial femoral  condyle  in  11  patients,  lateral  femoral  condyle  in  two  patients,  and  both  femoral
condyles  in  one  patient.  Mean  defect  surface  area  after  debridement  was  2.1  cm2 (1—6.3).
Results:  After  a  mean  follow-up  of  six  years,  improvements  were  noted  in  12  (86%)  patients,
with an  International  Knee  Documentation  Committee  (IKDC)  score  increase  from  40  (27.6—65.5)
to 60.2  (35.6—89.6)  (P  =  0.003)  and  a  Brittberg-Perterson  score  decrease  from  54.4  (11.8—98.2)
to 32.9  (0—83.9)  (P  =  0.02),  between  the  preoperative  assessment  and  last  follow-up.  The  visual
analogic scale  pain  score  decreased  from  66.3  (44—89)  to  23.2  (0—77)  (P  =  0.0006).  In  two
(14%) patients,  no  improvements  were  detectable  at  last  follow-up.  The  remaining  12  patients
were satisﬁed  and  able  to  resume  sporting  activities,  albeit  at  a  less  strenuous  level.  Two  ACI-
speciﬁc complications  occurred,  namely,  periosteal  hypertrophy  treated  with  debridement  in
one patient  and  transplant  delamination  in  another.
∗ Corresponding author.
E-mail address: anthony.viste@chu-lyon.fr (A. Viste).
1877-0568/$ – see front matter © 2012 Published by Elsevier Masson SAS.
doi:10.1016/j.otsr.2012.04.019
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Discussion:  Our  ﬁndings  are  consistent  with  previous  reports  but  cover  a  longer  follow-up
period. Although  the  outcomes  are  promising,  longer  follow-ups  are  needed  to  conﬁrm  the
long-term  effectiveness  of  ACI.
Level  of  evidence:  IV,  prospective  therapeutic  study.
© 2012  Published  by  Elsevier  Masson  SAS.
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he  treatment  of  deep  chondral  defects  located  in  load-
earing  areas  and  measuring  more  than  1  cm2 (grades  III
nd  IV  in  the  International  Cartilage  Repair  Society  [ICRS]
lassiﬁcation)  continues  to  generate  considerable  interest
1].  Grade  III  defects  reach  the  subchondral  bone,  whereas
rade  IV  lesions  extend  into  the  subchondral  bone.  In  one
tudy,  patients  younger  than  40  years  of  age  with  grade  IV
esions  accounted  for  5%  of  all  arthroscopies  [2].  Knee  car-
ilage  injuries  are  often  due  to  acute  traumatic  injuries.  Of
atients  with  acute  traumatic  hemarthrosis  of  the  knee,  5%
o  10%  have  deep  chondral  defects  [3].
Chondral  defects  can  cause  early  osteoarthritis  [4,5]
ecause  the  hyaline  joint  cartilage  has  a  limited  intrinsic
otential  for  repair.  Chondrocytes  are  unable  to  migrate  to
he  site  of  injury.  Partial  or  superﬁcial  defects  (as  opposed
o  deep  defects)  can  undergo  spontaneous  repair  from  the
djacent  cells.  The  ﬁlling  of  deep  defects,  in  contrast,
equires  cell  migration  over  considerably  greater  distances.
echniques  used  to  repair  deep  chondral  defects  have
ncluded  microfracture  [6]  and  mosaicplasty  [7].  Microfrac-
ure  techniques  lead  to  the  production  of  ﬁbrocartilage,
hich  has  less  mechanical  strength  compared  to  native
artilage.  Mosaicplasty  consists  in  transplanting  hyaline  car-
ilage  plugs  taken  from  non-load-bearing  sites.
Autologous  cartilage  implantation  (ACI)  is  an  alternative
o  microfracture  and  mosaicplasty.  ACI  leads  to  the  synthesis
f  hyaline  cartilage  containing  type  II  collagen  [8].  The  ﬁrst
CI  procedure  in  a  human  patient  was  performed  in  Sweden
n  1987  to  treat  a  knee  injury.  The  team  led  by  Brittberg
nd  Peterson  [9]  published  a  study  of  ACI  outcomes  in  1994
10]. They  used  autologous  chondrocytes  collected  from  the
njured  knee  then  subjected  to  cell  engineering  techniques
esigned  to  enhance  their  regenerative  capabilities.
The  objective  of  this  prospective  study  was  to  evaluate
he  medium-term  functional  outcomes  of  ACI  in  14  ath-
etes  with  post-traumatic  cartilage  defects  of  the  knee.  Our
ypothesis  was  that  ACI  might  be  effective  in  ﬁlling  deep
hondral  defects  at  the  knee.
atients and methods
atients
etween  2001  and  2006,  we  included  14  patients  in  a
rospective  single-centre  study.  Our  institutional  review
oard  approved  the  research  protocol  (study  #010028)  and
ll  patients  gave  their  written  informed  consent  prior  to
tudy  inclusion.
E
P
sInclusion criteria  were  a  visual  analogic  scale  (VAS)  pain
core  less  than  40/100,  age  18  to  50  years,  grade  III  or
V  chondral  defect  in  a  load-bearing  area,  defect  size
ess  or  equal  to  1  cm2,  and  written  informed  consent.  We
xcluded  patients  with  greater  than  ﬁve  of  knee  varum  or
algum,  knee  laxity,  and/or  radiological  evidence  of  knee
steoarthritis.
perative  technique
CI  was  performed  in  two  steps  as  recommended  by  Brit-
berg  and  Peterson  [9].  Arthroscopy  was  performed  with
 tourniquet.  The  defect  was  inspected  and  its  size  was
etermined  with  the  help  of  a  probe  of  known  dimensions.
artilage  was  collected  from  the  upper  part  of  the  medial
emoral  condyle  of  the  same  knee  for  culturing  prior  to  re-
mplantation.  In  the  operating  room,  the  cartilage  samples
ere  placed  in  a  sterile  container  ﬁlled  with  0.9%  saline  at
oom  temperature.  The  samples  were  then  taken  to  the  cell
ulture  laboratory.
At the  laboratory,  after  enzymatic  digestion  of  the
xtracellular  matrix,  the  cells  were  grown  to  monolayers
xhibiting  dedifferentiation  (phenotypic  instability)  with  a
broblast-like  appearance  and  limited  matrix  production
collagens  types  I  and  III  and  non-cartilage  proteoglycans)
ollowed  by  re-differentiation.  The  mean  number  of  har-
ested  cells  was  161,375  (32,000  to  375,000)  and  the  mean
eight  of  collected  cartilage  was  402.9  mg  (240  to  780  mg).
Cell  implantation  was  performed  six  weeks  later.  Prophy-
actic  antibiotic  therapy  was  given  at  the  time  of  anaesthesia
nduction.  An  arthrotomy  incision  was  made,  and  the  chon-
ral  lesion  was  debrided  (Fig.  1).  A  periosteal  ﬂap  taken  from
he  superomedial  part  of  the  tibia  was  sutured,  in  its  origi-
al  orientation,  to  the  surrounding  rim  of  normal  cartilage,
sing  Vicryl  5/0  or  6/0  (Fig.  2).  The  cultured  chondrocytes
ere  injected  under  the  ﬂap  (suspended  in  0.5  mL  [0.2  to
 mL]  in  a  syringe  in  a  sterile  package).  The  mean  num-
er  of  implanted  chondrocytes  was  13.3  ×  106 (0.2  ×  106 to
7  ×  106).  Fibrin  glue  was  used  to  seal  the  rim  of  the  lesion.
ean  operative  time  was  96  minutes  (57—150  minutes).
Postoperative  care  was  standardized.  Continuous  passive
obilization  from  0  to  60  was  started  on  day  3.  Weight
earing  was  forbidden  for  six  weeks.  Resumption  of  sporting
ctivities  was  allowed  after  six  months.
All  procedures  were  performed  by  the  same  senior  sur-
eon  (BM).
valuationatients  were  evaluated  preoperatively  then  after  three,
ix,  nine,  and  12  months;  after  3.5  years;  and  at  last
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Figure  1  Cartilage  defect  after  debridement.
two  occasional  recreational  athletes.  Mean  body  mass  index
was  26  kg/m2 (18.7—32.6  kg/m2)  (Table  1).
All  the  study  patients  had  deep  chondral  defects  (ICRS
grade  III  in  three  patients  and  IV  in  11  patients)  caused  by
an  injury  sustained  during  sporting  activities  (n  =  11),  motor
vehicle  accidents  (n  =  2),  or  work  (n  =  1).  Ten  patients  had
had  11  previous  procedures  on  the  same  knee  consisting
in  microfracture  (n  =  3),  Pridie  procedure  (n  =  1),  meniscec-
tomy  (n  =  2),  anterior  cruciate  ligament  repair  (n  =  2),  and
arthroscopic  debridement  (n  =  3).
Mean  time  from  injury  to  ACI  was  2.9  years  (0.5—7
years).  The  defect  was  on  the  medial  femoral  condyle  in  11
patients,  the  lateral  femoral  condyle  in  two  patients,  and
both  condyles  in  one  patient.  Mean  defect  size  was  2.1  cm2
(1—6.3  cm2).
Complications
We  recorded  two  early  complications  (hemarthrosis
drained  on  day  8  and  pulmonary  embolism)  and  three
late  complications  (periosteal  hypertrophy  managed  with
debridement,  transplant  delamination,  and  reﬂex  sympa-
thetic  dystrophy  syndrome).  No  infections  occurred.  At
last  follow-up,  the  patient  with  periosteal  hypertrophy  had
a  functional  Brittberg-Peterson  score  of  52  and  an  IKDC
score  of  78.  The  patient  with  transplant  delamination  had  a
functional  Brittberg-Peterson  score  of  84  and  an  IKDC  score
of  36.
Functional  outcomes
The  mean  VAS  pain  score  was  65.5/100  (44—80)  preoper-
atively  and  29/100  (0—66)  after  three  months  (P  =  0.0006)
then  remained  stable  over  time  (Fig.  3).  A  single  patient
had  no  improvement  in  pain  intensity  at  last  follow-up.
The  mean  preoperative  subjective  IKDC  score  (Fig.  4)  was
41  (28—65.5).  At  last  follow-up,  the  IKDC  score  indicated  an
excellent  outcome  in  three  patients,  a  good  outcome  in  ﬁve
patients,  and  a  fair  outcome  in  six  patients.  The  IKDC  score
improvement  was  statistically  signiﬁcant  (P  =  0.003).
The  mean  Brittberg-Peterson  score  was  54  (11.8—98.2)
preoperatively,  20  (1.8—47.5)  after  one  year  and  30  (0—84)
at  last  follow-up  (Fig.  5)  (P  =  0.02).  This  score  failed  to
improve  in  two  patients  (from  45  to  58  in  one  patient  and
from  58  to  84  in  the  other).Figure  2  Repair  using  autologous  chondrocyte  implantation
under a  periosteal  ﬂap.
follow-up.  Three  scores  were  determined  at  each  evalua-
tion.  The  VAS  pain  score  could  range  from  0  (no  pain)  to
100  (worst  pain  imaginable).  The  subjective  International
Knee  Documentation  Committee  (IKDC)  scale  has  ten  items
and  a  maximal  value  of  100;  scores  of  90  to  100  indicate
excellent  outcomes,  80  to  89  good  outcomes,  70  to  79  fair
outcomes,  and  less  than  70  poor  outcomes.  The  Brittberg-
Peterson  score  [11]  is  obtained  using  a  13-item  questionnaire
on  daily  activities  and  can  range  from  0  (no  symptoms)  to
130  (worst  possible  symptoms).
Statistical  analyses  were  performed  using  JMP  7.0  soft-
ware.  The  Wilcoxon  signed-rank  test  was  used  to  compare
quantitative  data.  Values  of  P  smaller  than  0.05  were  con-
sidered  signiﬁcant.
Results
Mean  follow-up  was  six  years  (3.3—7.8  years).  Mean  age  at
ACI  was  37.7  years  (30—45  years).  The  seven  men  and  seven
women  participated  actively  in  sporting  activities;  six  were
competitive  athletes,  six  regular  recreational  athletes,  and Figure  3  Mean  visual  analogic  scale  pain  scores  over  time.
740  A.  Viste  et  al.
Table  1  Study  population.
Patients  Age  (years)  Sex  BMI  (kg/m2)  Injury  Defect  size  (cm2)  Improved
1  45  Female  28.30  Sports  2  Yes
2 37  Male  24.69  Sports  3.5  Yes
3 35  Male  32.61  Sports  2.9  Yes
4 40  Female  23.73  Sports  1.2  Yes
5 36  Female  30.83  Sports  1.4  Yes
6 42 Male  29.41  Work  2  Yes
7 37 Female  18.73  Motor  vehicle  1  Yes
8 45 Male 22.94  Sports  1.7  Yes
9 30 Male 24.44  Sports 2.6  Yes
10 36 Male 23.80  Sports 6.3  No
11 36  Female  29.41  Sports  1  Yes
12 40  Male  31.16  Sports  1.8  No
13 34  Female  21.37  Motor  vehicle  1  Yes
14 35  Female  21.88  Sports  1.4  Yes
Figure  4  Subjective  International  Knee  Documentation  Com-
mittee  (IKDC)  score.
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four  major  speciﬁc  complications:  transplant  hypertrophy,Figure  5  Brittberg-Peterson  score.
At  last  follow-up,  12  (86%)  patients  were  improved.  The
hree  evaluation  scores  showed  similar  time  patterns,  with
igniﬁcant  improvements  as  early  as  six  months  after  ACI.
iscussion
ur  prospective  study  was  designed  to  determine  whether
CI  in  athletes  with  post-traumatic  knee  cartilage  defects
roduced  functional  improvements  similar  to  those  reported
n  the  literature  [11]. Strong  points  of  our  study  include  the
d
s
cix-year  follow-up  and  prospective  design.  The  limitations
re  the  small  sample  size  and  absence  of  a  control  group.
Our  results  are  consistent  with  those  reported  previously
ut  were  obtained  after  a  longer  follow-up.  In  previous  stud-
es,  10%  to  30%  of  patients  were  unsatisﬁed  with  the  results
12,13]  (Table  2).
One  year  after  ACI,  86%  of  patients  [14,15]  had  improve-
ents  in  their  functional  scores,  which  were  sustained  after
hree  years  (84%  in  the  prospective  study  by  Micheli  et  al.
13]). In  a  retrospective  study,  the  rate  of  good  results  after
ve  years  was  89%  (84%  in  our  study).  The  Brittberg-Peterson
core  deteriorated  after  ﬁve  years,  as  reported  previously
fter  mosaicplasty  [19].
Krishnan  et  al.  [20]  have  indicated  that  criteria  asso-
iated  with  better  ACI  outcomes  consist  of  young  age,  a
ime  since  injury  shorter  than  two  years,  a  single  defect,
ocation  of  the  defect  on  the  trochlea  or  lateral  condyle,
nd  less  than  two  previous  procedures  on  the  same  knee.
n  our  study,  the  patients  with  defects  less  than  1  cm2 in
ize  had  previously  undergone  other  cartilage  repair  proce-
ures  that  had  decreased  the  size  of  the  defect  but  failed  to
chieve  complete  ﬁlling.  Given  the  persistent  symptoms  in
hese  patients,  we  performed  ACI.  In  our  study,  risk  factors
ere  the  mean  age  older  than  30  years,  the  2.6-year  time
rom  injury  to  ACI,  the  small  proportion  of  lateral  condyle
esions  (3/14  patients),  and  the  large  number  of  previous
rocedures  on  the  same  knee  (10/14  patients).
ACI  failure  occurs  chieﬂy  within  the  ﬁrst  two  years.  Fail-
re  rates  of  5%  to  16%  have  been  reported  [21,22]. A  crucial
tep  is  a  careful  preoperative  evaluation  of  risk  factors  for
ailure  [23]  such  as  marked  knee  varum  or  valgum,  meniscal
esions,  and  knee  laxity,  which  were  exclusion  criteria  in  our
tudy.  Strict  compliance  with  the  postoperative  rehabilita-
ion  program  is  necessary  to  prevent  failure  [24].
Transplant  hypertrophy  is  the  most  common  ACI-speciﬁc
omplication  and  becomes  apparent  three  to  seven  months
fter  the  procedure.  Niemeyer  et  al.  [25]  identiﬁedisturbed  fusion  of  the  regenerated  cartilage  with  the
urrounding  cartilage,  insufﬁcient  amount  of  regenerated
artilage,  and  delamination.  Non-speciﬁc  complications
Knee  chondrocyte  implantation:  Functional  outcomes  741
Table  2  Literature  review.
Authors  Number  of  patients  Study  design  Defect  size  (cm2)  Follow-up  (years)  Proportion  improved  (%)
Minas  [12]  56  Prospective  4.3  2  87
Micheli [13]  50  Prospective  4.2  3  84
Bentley [14]
Bentley  [15]
58
58
Prospective
Prospective
4.7
4.7
1.5
10
88
83
Henderson  [16]  57  Prospective  3.7  1  81
Beris [17] 45 Prospective 5.33  8  89
Peterson [18] 58 Prospective 5.7  5.6  93
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reported  after  ACI  consist  of  motion  range  limitation,  chon-
dromalacia,  synovitis,  infection,  and  deep  vein  thrombosis.
Mishaps  in  the  chondrocyte  culturing  process  were  identiﬁed
for  5%  of  304  cultures  performed  in  1996  [26]  and  consisted
of  contamination,  cell  death,  culture  failure,  and  identiﬁ-
cation  errors.
The  optimal  size  of  the  cell  inoculum  remains  debated.
Cell  numbers  ranging  from  2.6  to  30  million  per  millilitre
have  been  used.  With  autologous  cells,  the  number  of  avail-
able  cells  is  limited  by  the  amount  of  cartilage  that  can  be
collected.
Coverage  of  the  chondrocytes  with  a  periosteal  ﬂap  is
the  ﬁrst-generation  method  used  for  ACI.  Problems  with
this  method  include  cell  leakage  due  to  incomplete  sealing,
incomplete  integration  of  the  ﬂap  into  the  surrounding  carti-
lage  and  ﬂap  hypertrophy  [13,27],  and  uneven  chondrocyte
distribution  throughout  the  defect.  These  problems  can  be
avoided  by  using  a  collagen  or  matrix  membrane  [8,28,29].
Autologous  chondrocyte  implantation  (ACI)  vs.
microfracture
Knutsen  et  al.  [21,30]  compared  ACI  with  microfracture  in
80  patients  managed  at  four  centers  in  Norway.  The  defect
was  trauma-related  in  65%  of  cases,  mean  symptom  dura-
tion  was  three  years,  and  94%  of  patients  had  had  previous
surgical  procedures  on  the  same  knee.  After  two  years,  sim-
ilar  improvements  were  seen  in  the  Lysholm  score  and  pain
score  in  the  two  groups.  The  pain  score  was  improved  in  78%
of  the  ACI  patients  and  75%  of  the  microfracture  patients.
The  two-year  failure  rate  was  5%  with  ACI  and  2.5%  with
microfracture.  Periosteal  hypertrophy  was  the  main  reason
for  re-operation.  Macroscopic  arthroscopy  ﬁndings  after  two
years  were  not  different  in  the  two  groups.  Examination  of
67  biopsies  showed  no  between-group  differences  in  terms
of  proportions  of  hyaline  cartilage  and  of  ﬁbrocartilage  ﬁll-
ing  the  defects.  The  authors  concluded  that  short-term
outcomes  were  comparable  with  the  two  treatments.  It  is
worth  noting  that  partial  weight-bearing  was  allowed  in  both
groups,  which  may  have  contributed  to  induce  periosteal
ﬂap  lesions.  The  periosteal  ﬂap  is  particularly  fragile  after
ACI.
Kon  et  al.  [31]  compared  second-generation  ACI  (with
a  hyaluronan  scaffold,  Hyalograft  C)  and  microfracture  in
80  patients  with  a  mean  age  of  29.8  years  (40  patients  in
each  group)  in  a  non-randomised  ﬁve-year  study.  Each  pro-
cedure  was  performed  in  two  different  centres.  Mean  defect
e
t
a
c6 86
ize  was  2.4  cm2 and  over  50%  of  the  defects  were  trauma-
elated.  Subjective  IKDC  score  improvements  occurred  in
oth  groups:  the  score  increased  from  40  to  80  after  ACI
nd  from  40  to  70  after  microfracture.  Return  to  sports
as  similar  in  the  two  groups  after  two  years  but  deterio-
ated  subsequently  in  the  microfracture  group.  The  authors
oncluded  that  second-generation  ACI  was  superior  over
icrofracture.
utologous  chondrocyte  implantation  (ACI)  vs.
osaicplasty
wo  trials  compared  ACI  with  mosaicplasty,  with  conﬂicting
esults.  Horas  et  al.  [32]  compared  ACI  and  autologous  osteo-
hondral  plug  transplantation  in  40  patients  with  single
emoral  condyle  defects.  In  this  single-centre,  randomised,
wo-year  trial,  the  Meyers  and  Tegner  scores  were  similar  in
he  two  groups.  The  Lysholm  score  improvement  occurred
t  a  signiﬁcantly  slower  pace  in  the  ACI  group.  After  two
ears,  two  ACI  patients  and  three  mosaicplasty  patients
ere  unconvinced  that  the  procedure  had  been  beneﬁ-
ial.  Partial  failure  was  diagnosed  in  one  ACI  patient,  who
nderwent  re-operation.  No  failures  were  reported  in  the
osaicplasty  group.  The  biopsies  showed  that  ACI  produced
hieﬂy  ﬁbrocartilage,  with  foci  of  hyaline-like  cartilage  near
he  subchondral  bone.  In  the  mosaicplasty  group,  the  histo-
ogical  ﬁndings  indicated  good  integration  of  the  implants
nto  the  surrounding  cartilage.  Limitations  of  this  study  are
he  small  sizes  of  both  groups,  short  follow-up,  and  absence
f  a  control  group.
Bentley  et  al.  [14]  compared  ACI  and  mosaicplasty  in
 randomised  trial  in  100  patients  (mean  age,  31  years),
ith  post-traumatic  cartilage  defects.  The  modiﬁed  Cincin-
ati  score  and  objective  clinical  evaluation  indicated  good
nd  excellent  results  in  88%  of  patients  with  ACI  and  69%
ith  mosaicplasty.  Excellent  or  good  repair  as  assessed  by
rthroscopy  after  one  year  was  noted  in  82%  of  patients  after
CI  and  34%  after  mosaicplasty.  This  is  the  only  prospec-
ive  randomized  trial  comparing  ACI  with  mosaicplasty.  The
natomic  results  as  assessed  arthroscopically  were  poorer
fter  mosaicplasty,  with  66%  of  unchanged  or  worsened
efects  according  to  ICRS  criteria  compared  to  only  18%  after
CI.  Biopsies  were  taken  during  the  one-year  arthroscopic
valuation  in  the  ACI  group  only.  They  showed  hyaline  car-
ilage  in  seven  of  19  patients,  a  mixture  of  hyaline  cartilage
nd  ﬁbrocartilage  in  seven  other  patients,  and  only  ﬁbro-
artilage  in  ﬁve  patients.  A  periosteal  ﬂap  was  used  early  in
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he  study  and  a  porcine  collagen  membrane  later  on.  After
ne  year,  no  difference  related  to  this  change  in  technique
as  noted.  No  complications  directly  related  to  either  treat-
ent  method  were  recorded.  The  authors  concluded  that
he  one-year  clinical  outcomes  were  good  with  both  meth-
ds  and  that  the  arthroscopy  data  indicated  better  repair  in
he  ACI  group.
The  results  of  the  two  trials  comparing  ACI  and  mosaic-
lasty  are  divergent.  Bentley  et  al.  [14]  concluded  that  the
linical  outcomes  were  similar  after  one  year  but  that  the
rthroscopy  ﬁndings  were  more  favorable  after  ACI.  Horas
t  al.  [32]  reported  a  faster  pace  of  clinical  improvement
ver  the  ﬁrst  two  years  after  mosaicplasty,  with  arthroscopy
ndings  indicating  that  the  regenerative  cartilage  was  sim-
lar  to  the  surrounding  cartilage,  whereas  ﬁbrocartilage
redominated  after  ACI.  Several  differences  in  the  surgical
echniques  are  worth  noting.  The  size  of  the  mosaicplasty
lugs  was  10  or  16  mm  in  the  study  by  Horas  et  al.  com-
ared  to  only  4.5  mm  in  the  study  by  Bentley  et  al.  Bentley
t  al.  allowed  immediate  full  weight-bearing.  They  recently
eported  better  ten-year  outcomes  after  ACI  compared  to
osaicplasty  [15].
onclusion
ur  ﬁndings  are  encouraging,  although  the  scores  started  to
mprove  one  year  after  the  procedure  then  remained  stable
ntil  last  follow-up.
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